DIAGENS-B (02526) has officially entered into a cooperative framework agreement with Zhejiang Anzhen'er Medical Artificial Intelligence Technology Co., Ltd. (Anzhen'er), marking a significant step forward in the field of medical imaging artificial intelligence, grassroots imaging cloud services, and healthcare data products. The partnership, which takes effect from the date of signing, is structured to run for a three-year term.

Under the terms of this collaboration, both parties intend to integrate the group's iMedImage® multimodal medical imaging capabilities with Anzhen'er's unique resources to jointly establish a provincial-level 鈥淒igital Intelligent Imaging鈥 capability foundation. This initiative aims to create a benchmark for provincial medical large-model applications, focusing on pre-consultation support, preliminary imaging screening, and report interpretation. Furthermore, leveraging Anzhen'er's pilot base operations and its collaborative resources with medical institutions, the agreement explores an innovative imaging cloud service model characterized by 鈥渆xaminations at the grassroots level, recognition in the cloud, and review at the provincial level,鈥 ultimately working toward the development of a province-wide AI-assisted diagnostic imaging cloud platform for Zhejiang.

The collaboration also extends to the joint development of high-quality medical datasets, AI training corpora, and scientific research and data analysis products, with the goal of pioneering new models for the assetization of medical data. The board of directors believes this partnership will effectively combine the group's foundational medical imaging models and software-hardware product capabilities with the medical resource coordination, clinical scenario organization, and technology transfer support offered by a national-level pilot base. Through specific projects, the initiative seeks to drive collaborative innovation among medical institutions, research entities, and enterprises around clinical needs, while exploring the development, validation, and application of high-quality datasets, specialized disease models, and innovative products. This approach is expected to elevate the ceiling of medical research and diagnostic innovation.

Additionally, the group plans to expand its model services by exploring a token-based usage pricing model, where tokens serve as the unit of measurement for information processed by the models. This strategy would enable medical institutions to access premium imaging analysis capabilities on demand, thereby lowering adoption barriers and extending services to grassroots diagnostics and out-of-hospital health management. By broadening the commercial potential of model services, the initiative aims to raise the baseline of primary healthcare capabilities and, through establishing a new exemplary model of 鈥淗ealthy China鈥 in Zhejiang, accelerate the delivery of AI technology benefits to a wider population. Ultimately, this cooperation is poised to unlock new commercialization avenues for model services, promote the application of AI in disease prevention, health risk prediction, and diagnostics, and align with the overall interests of both the company and its shareholders.